NO980154L - Sykliske GMP-spesifikke fosfodiesteraseinhibitorer - Google Patents

Sykliske GMP-spesifikke fosfodiesteraseinhibitorer

Info

Publication number: NO980154L
Authority: NO; Norway
Prior art keywords: alkyl; phosphodiesterase inhibitors; cyclic gmp; hydrogen; specific phosphodiesterase
Prior art date: 1995-07-14

Application number

NO980154A

Other languages

English (en)

Norwegian (no)

Other versions

NO980154D0 (no

Inventor

Alain Claude-Marie Daugan

Francoise Gellibert

Original Assignee

Icos Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-14

Filing date

1998-01-13

Publication date

1998-03-10

1998-01-13 Application filed by Icos Corp filed Critical Icos Corp

1998-01-13 Publication of NO980154D0 publication Critical patent/NO980154D0/no

1998-03-10 Publication of NO980154L publication Critical patent/NO980154L/no

Links

ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 title abstract 2
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 title 1
239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical class 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
229940124639 Selective inhibitor Drugs 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO980154A 1995-07-14 1998-01-13 Sykliske GMP-spesifikke fosfodiesteraseinhibitorer NO980154L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9514465.5A GB9514465D0 (en)	1995-07-14	1995-07-14	Chemical compounds
PCT/EP1996/003025 WO1997003985A1 (en)	1995-07-14	1996-07-11	Cyclic gmp-specific phosphodiesterase inhibitors

Publications (2)

Publication Number	Publication Date
NO980154D0 NO980154D0 (no)	1998-01-13
NO980154L true NO980154L (no)	1998-03-10

Family

ID=10777696

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO980154A NO980154L (no)	1995-07-14	1998-01-13	Sykliske GMP-spesifikke fosfodiesteraseinhibitorer

Country Status (24)

Country	Link
US (1)	US5981527A (de)
EP (1)	EP0846118B1 (de)
JP (1)	JP4150818B2 (de)
CN (1)	CN1069318C (de)
AR (1)	AR003455A1 (de)
AT (1)	ATE216997T1 (de)
AU (1)	AU702324B2 (de)
BR (1)	BR9609780A (de)
CA (1)	CA2226761A1 (de)
CO (1)	CO4700455A1 (de)
CZ (1)	CZ3298A3 (de)
DE (1)	DE69621026T2 (de)
ES (1)	ES2176471T3 (de)
GB (1)	GB9514465D0 (de)
HR (1)	HRP960321B1 (de)
HU (1)	HUP9900006A3 (de)
IL (1)	IL122923A0 (de)
MX (1)	MX9800411A (de)
NO (1)	NO980154L (de)
PL (1)	PL324527A1 (de)
SK (1)	SK3898A3 (de)
WO (1)	WO1997003985A1 (de)
YU (1)	YU42296A (de)
ZA (1)	ZA965934B (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6143746A (en) *	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) *	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
US6060477A (en) *	1995-06-07	2000-05-09	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US5874440A (en) *	1995-06-07	1999-02-23	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6046206A (en) *	1995-06-07	2000-04-04	Cell Pathways, Inc.	Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6232312B1 (en)	1995-06-07	2001-05-15	Cell Pathways, Inc.	Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6262059B1 (en)	1995-06-07	2001-07-17	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with quinazoline derivatives
US6200980B1 (en)	1995-06-07	2001-03-13	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with phenyl purinone derivatives
GB9514473D0 (en) *	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
US6331543B1 (en)	1996-11-01	2001-12-18	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
AU756136B2 (en)	1997-06-23	2003-01-02	Queen's University At Kingston	Microdose therapy
ES2137113B1 (es)	1997-07-29	2000-09-16	Almirall Prodesfarma Sa	Nuevos derivados de triazolo-piridazinas heterociclicos.
US5852035A (en) *	1997-12-12	1998-12-22	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) *	1998-01-14	2000-04-04	Cell Pathways, Inc.	Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en)	1998-01-14	2002-06-25	Cell Pathways, Inc.	Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) *	1998-01-27	1999-08-24	Cell Pathways, Inc.	Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) *	1998-04-15	1999-11-23	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6124303A (en) *	1998-09-11	2000-09-26	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en)	1998-09-11	2001-07-31	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6326379B1 (en)	1998-09-16	2001-12-04	Bristol-Myers Squibb Co.	Fused pyridine inhibitors of cGMP phosphodiesterase
US6200771B1 (en)	1998-10-15	2001-03-13	Cell Pathways, Inc.	Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) *	1998-11-19	2000-10-17	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en)	1998-11-20	2001-02-13	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en)	1998-11-23	2002-04-09	Cell Pathways, Inc.	Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) *	1998-11-24	2000-03-07	Cell Pathways, Inc.	Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) *	1998-11-24	2000-06-20	Cell Pathways, Inc.	Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6486155B1 (en)	1998-11-24	2002-11-26	Cell Pathways Inc	Method of inhibiting neoplastic cells with isoquinoline derivatives
US6020379A (en) *	1999-02-19	2000-02-01	Cell Pathways, Inc.	Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6613768B1 (en)	1999-04-30	2003-09-02	Lilly Icos Llc	Treatment of female arousal disorder
ES2187234A1 (es) *	1999-04-30	2003-05-16	Lilly Icos Llc	Forma de dosificacion oral para tratar la disfuncion sexual.
US6451807B1 (en)	1999-04-30	2002-09-17	Lilly Icos, Llc.	Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
PT1200090E (pt) *	1999-08-03	2013-11-25	Icos Corp	Formulação farmacêutica à base de um beta-carbolina e seu uso para tratar a disfunção sexual.
AU7766300A (en) *	1999-10-07	2001-05-10	Novaneuron Inc.	Gene necessary for striatal function, uses thereof, and compounds for modulatingsame
US20040152106A1 (en) *	1999-10-07	2004-08-05	Robertson Harold A.	Gene necessary for striatal function, uses thereof, and compounds for modulating same
HK1049834A1 (zh)	1999-10-11	2003-05-30	辉瑞大药厂	用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
US20040254153A1 (en) *	1999-11-08	2004-12-16	Pfizer Inc	Compounds for the treatment of female sexual dysfunction
IL139457A0 (en)	1999-11-08	2001-11-25	Pfizer	Compounds for the treatment of female sexual dysfunction
US6569638B1 (en)	2000-03-03	2003-05-27	Cell Pathways, Inc	Method for screening compounds for the treatment of neoplasia
US6774128B2 (en) *	2000-04-19	2004-08-10	Johns Hopkins University	Methods for prevention and treatment of gastrointestinal disorders
US20020006926A1 (en)	2000-04-19	2002-01-17	Roylance H. H.	Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
MXPA02012470A (es)	2000-06-23	2004-01-26	Lilly Icos Llc	Inhibidores de fosfodiesterasa especificos para gmp ciclico.
WO2002010166A1 (en) *	2000-08-02	2002-02-07	Lilly Icos Llc	Fused heterocyclic derivatives as phosphodiesterase inhibitors
US6503894B1 (en)	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
CN1264574C (zh) *	2000-09-06	2006-07-19	田边制药株式会社	口服制剂
US6821978B2 (en)	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
US6962918B2 (en) *	2000-10-02	2005-11-08	Lilly Icos Llc.	Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
CA2423308A1 (en)	2000-10-02	2002-04-11	Lilly Icos Llc	Condensed pyridoindole derivatives
ATE337320T1 (de)	2000-11-06	2006-09-15	Lilly Icos Llc	Indolderivate als pde5-inhibitoren
MXPA03004023A (es)	2000-11-08	2004-02-12	Lilly Icos Llc	Compuestos quimicos.
NZ527585A (en) *	2001-02-15	2005-04-29	Tanabe Seiyaku Co	Tablets quickly disintegrated in oral cavity
DE10118306A1 (de)	2001-04-12	2002-10-17	Bayer Ag	Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE10118305A1 (de) *	2001-04-12	2002-10-17	Bayer Ag	Zusammensetzungen zur nasalen Applikation
ATE360422T1 (de) *	2001-06-05	2007-05-15	Lilly Icos Llc	Tetrazyklische verbindungen als pde5-inhibitoren
DE60213798T2 (de) *	2001-06-21	2007-08-16	Lilly Icos Llc, Wilmington	Carbolinderivate als pdev inhibitoren
CA2465893A1 (en) *	2001-11-09	2003-05-22	Schering Corporation	Polycyclic guanine derivative phosphodiesterase v inhibitors
DE60235198D1 (de) *	2001-12-20	2010-03-11	Merck Serono Sa Coinsins	Pyrrolidin-derivatie als prostaglandin-modulatoren
US7208516B2 (en)	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en)	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
NZ537784A (en) *	2002-07-31	2008-01-31	Lilly Icos Llc	Modified Pictet-Spengler reaction and products prepared therefrom
JP2007501866A (ja) *	2003-06-13	2007-02-01	マイクロバイアインコーポレイテッド	胃腸疾患の治療のための方法および組成物
EP2216329A1 (de) *	2004-10-28	2010-08-11	Dr. Reddy's Laboratories Ltd.	Verfahren zur Herstellung von Tadalafil
US8506934B2 (en)	2005-04-29	2013-08-13	Robert I. Henkin	Methods for detection of biological substances
EP2258358A3 (de)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
JP2009514969A (ja)	2005-11-09	2009-04-09	コンビナトアールエックスインコーポレーティッド	医学的状態を治療するための方法、組成物、およびキット
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2382975A3 (de)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenese mittels Angiotensin-Modulation
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
AU2007292848A1 (en) *	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2008095136A2 (en)	2007-01-31	2008-08-07	Henkin Robert I	Methods for detection of biological substances
US8580801B2 (en)	2008-07-23	2013-11-12	Robert I. Henkin	Phosphodiesterase inhibitor treatment
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use
WO2014055801A1 (en)	2012-10-05	2014-04-10	Henkin Robert I	Phosphodiesterase inhibitors for treating taste and smell disorders
CN104230960B (zh) *	2013-06-06	2017-02-15	山东轩竹医药科技有限公司	四并环类间变性淋巴瘤激酶抑制剂
US20160317542A1 (en)	2013-12-09	2016-11-03	Respira Therapeutics, Inc.	Pde5 inhibitor powder formulations and methods relating thereto
CN104804016B (zh) *	2014-01-23	2017-06-20	山东轩竹医药科技有限公司	四并环类间变性淋巴瘤激酶抑制剂
US10598672B2 (en)	2014-02-18	2020-03-24	Cyrano Therapeutics, Inc.	Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
MX2016014384A (es)	2014-06-23	2017-01-20	Celgene Corp	Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
EP3728266A1 (de)	2017-12-20	2020-10-28	Novartis AG	Kondensierte tricyclische pyrazolo-dihydropyrazinyl-pyridonverbindungen als viruzide
JP7348906B2 (ja)	2018-02-28	2023-09-21	フェロセラピューティクス，インコーポレイテッド	フェロトーシス誘導活性を有する化合物およびそれらの使用方法
US11040964B2 (en)	2019-02-27	2021-06-22	Ferro Therapeutics, Inc.	Compounds and methods of use
JP7606530B2 (ja)	2020-03-24	2024-12-25	シラノセラピューティクス，インコーポレイテッド	コロナウイルス感染症による化学感覚機能障害の治療
EP4684777A1 (de)	2024-07-24	2026-01-28	Adalvo Limited	Pharmazeutische zusammensetzung mit fixer dosis mit (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropansäure und (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,12,12a-hexahydropyrido[3,4-b!indol-1,4-dion

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3644384A (en) *	1969-06-09	1972-02-22	Sterling Drug Inc	Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) *	1971-03-11	1973-02-20	Sterling Drug Inc	1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) *	1973-03-30	1975-11-04	Council Scient Ind Res	2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) *	1973-10-19	1976-10-27	Council Scient Ind Res	Tetracyclic compounds
US4188390A (en) *	1977-11-05	1980-02-12	Pfizer Inc.	Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GR79603B (de) *	1982-07-24	1984-10-31	Pfizer
IT1217190B (it) *	1988-04-22	1990-03-14	Recordati Chem Pharm	Composti utili per il trattamento e diagnosi di disfunzioni frettili
EP0357122A3 (de) *	1988-08-29	1991-10-23	Duphar International Research B.V	Verwendung von Beta-Carbolinen und deren bio-isosterischen Benzofuran- und Benzothiophenanalogen zur Herstellung eines Arzneimittels mit cytostatischer Wirkung
DE3830096A1 (de) *	1988-09-03	1990-03-15	Hoechst Ag	Piperazindione mit psychotroper wirkung
FR2649613B1 (fr) *	1989-07-11	1991-09-27	Virag Ronald	Medicament vaso-actif
JPH0344324A (ja) *	1989-07-13	1991-02-26	Kazuoki Tsuchiya	性機能賦活剤
US5270323A (en) *	1990-05-31	1993-12-14	Pfizer Inc.	Method of treating impotence
EP0459666B1 (de) *	1990-05-31	1994-11-09	Pfizer Inc.	Arzneimittel gegen Impotenz
GB9013750D0 (en) *	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
GB9114760D0 (en) *	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
GB9218322D0 (en) *	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
GB9311920D0 (en) *	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
GB9401090D0 (en) *	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds

1995
- 1995-07-14 GB GBGB9514465.5A patent/GB9514465D0/en active Pending
1996
- 1996-07-05 HR HR960321A patent/HRP960321B1/xx not_active IP Right Cessation
- 1996-07-11 SK SK38-98A patent/SK3898A3/sk unknown
- 1996-07-11 PL PL96324527A patent/PL324527A1/xx unknown
- 1996-07-11 US US09/000,192 patent/US5981527A/en not_active Expired - Lifetime
- 1996-07-11 EP EP96923986A patent/EP0846118B1/de not_active Expired - Lifetime
- 1996-07-11 AU AU64192/96A patent/AU702324B2/en not_active Ceased
- 1996-07-11 HU HU9900006A patent/HUP9900006A3/hu unknown
- 1996-07-11 ES ES96923986T patent/ES2176471T3/es not_active Expired - Lifetime
- 1996-07-11 WO PCT/EP1996/003025 patent/WO1997003985A1/en not_active Ceased
- 1996-07-11 BR BR9609780A patent/BR9609780A/pt not_active Application Discontinuation
- 1996-07-11 CA CA002226761A patent/CA2226761A1/en not_active Abandoned
- 1996-07-11 IL IL12292396A patent/IL122923A0/xx unknown
- 1996-07-11 DE DE69621026T patent/DE69621026T2/de not_active Expired - Fee Related
- 1996-07-11 AT AT96923986T patent/ATE216997T1/de active
- 1996-07-11 CN CN96196751A patent/CN1069318C/zh not_active Expired - Fee Related
- 1996-07-11 JP JP50624997A patent/JP4150818B2/ja not_active Expired - Fee Related
- 1996-07-11 MX MX9800411A patent/MX9800411A/es not_active Application Discontinuation
- 1996-07-11 CZ CZ9832A patent/CZ3298A3/cs unknown
- 1996-07-12 YU YU42296A patent/YU42296A/sh unknown
- 1996-07-12 CO CO96036775A patent/CO4700455A1/es unknown
- 1996-07-12 AR ARP960103558A patent/AR003455A1/es unknown
- 1996-07-12 ZA ZA9605934A patent/ZA965934B/xx unknown
1998
- 1998-01-13 NO NO980154A patent/NO980154L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0846118A1 (de)	1998-06-10
WO1997003985A1 (en)	1997-02-06
JPH11509535A (ja)	1999-08-24
HRP960321B1 (en)	2003-06-30
PL324527A1 (en)	1998-06-08
NO980154D0 (no)	1998-01-13
MX9800411A (es)	1998-04-30
ATE216997T1 (de)	2002-05-15
IL122923A0 (en)	1998-08-16
BR9609780A (pt)	1999-03-09
DE69621026T2 (de)	2002-08-22
EP0846118B1 (de)	2002-05-02
HRP960321A2 (en)	1998-08-31
JP4150818B2 (ja)	2008-09-17
AR003455A1 (es)	1998-08-05
CZ3298A3 (cs)	1998-06-17
CO4700455A1 (es)	1998-12-29
ZA965934B (en)	1997-02-03
ES2176471T3 (es)	2002-12-01
AU6419296A (en)	1997-02-18
HUP9900006A2 (hu)	1999-04-28
DE69621026D1 (de)	2002-06-06
CN1069318C (zh)	2001-08-08
YU42296A (sh)	1998-12-23
SK3898A3 (en)	1998-11-04
AU702324B2 (en)	1999-02-18
GB9514465D0 (en)	1995-09-13
CA2226761A1 (en)	1997-02-06
HUP9900006A3 (en)	1999-11-29
US5981527A (en)	1999-11-09
CN1195349A (zh)	1998-10-07

Legal Events

Date	Code	Title	Description
2001-03-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO980154L (no)	1998-03-10	Sykliske GMP-spesifikke fosfodiesteraseinhibitorer
DK0770065T3 (da)	2004-07-19	Trisubstituerede phenylderivater nyttige som PDE IV-inhibitorer
NO20083684L (no)	2004-05-03	Laktam-inneholdende forbindelser og derivater derav som faktor XA-inhibitorer
NO20071702L (no)	2007-05-25	Fremgangsmate for fremstilling av 4,5-dihydro-pyrazolo[3,4-C]pyrid-oner
NO970512L (no)	1997-08-07	Nye heteroaryl-oksazolidinoner
DK0766670T3 (da)	2002-04-22	Tri-substituerede phenylderivater anvendelige som PDE IV inhibitorer
NO974595L (no)	1997-12-03	Imidazo£1,2-a\|pyridin-derivater
DK0640065T3 (da)	2001-11-12	Trisubstituerede phenylderivater som phosphodiesteraseinhibitorer og fremgangsmåder til deres fremstilling
CA2129039A1 (en)	1994-07-07	Tri-substituted phenyl derivatives as phosphodiesterase inhibitors
HUP0000487A2 (hu)	2001-02-28	Neurokinin antagonistaként alkalmazható szubsztituált oximszármazékok
DE69323732D1 (de)	1999-04-08	Styrylderivate und verfahren zu ihrer herstellung
YU49898A (sh)	2000-03-21	Hemijska jedinjenja
CA2339630A1 (en)	2000-03-23	Carboline derivatives as cgmp phosphodiesterase inhibitors
HUP0102843A2 (hu)	2002-03-28	Eljárás (3-izoxazolinil)-acil-benzolok előállítására
NO982913L (no)	1998-07-30	Kinolin- og kinazolinforbindelser nyttige i terapi
AU5231598A (en)	1998-07-17	Triarylethanes useful as pde iv inhibitors
NO20025821L (no)	2003-02-04	2-aminokarbonyl-9H-purinderivater
TR200302268T4 (tr)	2004-01-21	NOS inhibitörleri olarak yararlı N-heterosiklik türevler.
MA22895A1 (fr)	1993-12-31	7-(2-aminoethyl) benzothiazolones.
NO20063132L (no)	2006-09-11	Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer
WO1999032449A3 (en)	1999-09-30	Benzazine derivatives as phosphodiesterase 4 inhibitors
HUP0303480A2 (hu)	2004-01-28	4-(2-Butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il)-pirazolo-[1,5-a]-1,3,5-triazin-származékok, mint CRF-antagonisták, és ezeket tartalmazó gyógyszerkészítmények
NO20022470L (no)	2002-07-18	Pyrimidinderivater
WO2003045901A3 (en)	2003-07-31	Guanidine derivatives
ATE384722T1 (de)	2008-02-15	Alkoxypyridinderivate